Skip to main content
PMC home page
Frontiers in Neurology logoLink to Frontiers in Neurology
. 2019 Mar 28;10:290. doi: 10.3389/fneur.2019.00290

Association Between Aldehyde dehydrogenase-2 Polymorphisms and Risk of Alzheimer's Disease and Parkinson's Disease: A Meta-Analysis Based on 5,315 Individuals

Jun Chen 1,†, Wei Huang 1,†, Chao-Hui Cheng 1, Lan Zhou 1,*, Guang-Bin Jiang 2,*, Yuan-Yuan Hu 3
PMCID: PMC6448532  PMID: 30984100

Abstract

Objective: A number of studies have reported that aldehyde dehydrogenase-2 (ALDH2) polymorphisms maybe associated with the risk of Alzheimer's disease (AD) and Parkinson's disease (PD). However, the results of such studies are inconsistent. We therefore conducted a meta-analysis to clarify the association between ALDH2 polymorphisms and the risk of AD and PD.

Methods: Five online databases were searched and the relevant studies were reviewed from inception through May 10, 2018. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated in each genetic model of the general population and various subgroups. Furthermore, we simultaneously performed heterogeneity, cumulative, sensitivity, and publication bias analyses.

Results: Overall, nine case-control studies involving 5,315 subjects were included in this meta-analysis. Potential associations were found between the ALDH2 rs671 G>A polymorphism and the risk of AD (A vs. G: OR = 1.46, 95%CI = 1.01–2.11, P = 0.05, I2 = 84.2%; AA vs. GG: OR = 2.22, 95%CI = 1.03–4.77, P = 0.04, I2 = 79.2%; AA vs. GG+GA: OR = 1.94, 95%CI = 1.03–3.64, P =0.04, I2 = 71.1%). In addition, some similar results were observed in other subgroups. Moreover, no significant association between ALDH2 polymorphisms and PD risk.

Conclusions: In conclusion, our meta-analysis indicated that the ALDH2 rs671 G>A polymorphism plays an important role in AD development.

Keywords: Aldehyde dehydrogenase 2, neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, polymorphism

Introduction

Neurodegenerative disorders are a family of heterogeneous disorders, in which progressive degeneration occurs in the structure and function of the central or peripheral nervous system (1). Neurodegenerative disorders would lead to progressive cognitive and motor disabilities, such as senile dementia, balance disorder, movement dyskinesia, and muscular tension abnormalities (2). Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative disorders (3).Currently, there are more than 5 million patients with AD and this number is projected to increase to 7.1 million by 2025 (4). Indeed, the World Health Organization has predicted that AD and other causes of dementia, as well as such as PD and amyotrophic lateral sclerosis will overtake cancer to become the second leading cause of death following cardiovascular disease (5). Further, as the population ages, AD and PD will increasingly place substantial burdens on not only the families of individuals with these conditions, but also on society as a whole.

AD and PD are closely related to aging, can have multiple causative factors, such as oxidative damage, abnormal protein deposition, and neuroinflammation (6). Other factors, including atherosclerosis (7), diabetes (8), neuroinflammation (9), and various environmental effects (10), have also been proposed as interactive factors for AD and PD (11). Moreover, increasing evidence suggests that genetic abnormities, including genetic mutations, play important roles in the development of AD and PD (12, 13).

One such gene that is thought to be involved in AD and PD is the aldehyde dehydrogenase-2 (ALDH2) gene. This gene is located on chromosome 12q24.12, comprises 13 exons and 12 introns, and encodes an important biologically active enzyme, ALDH2. This enzyme participates in the metabolism and detoxification of aldehyde, and it can metabolize short-chain aliphatic aldehydes and converted acetaldehyde into acetate. Moreover, ALDH2 is involved in the metabolism of other biogenic aldehydes, such as 4-hydroxynonenal, 3,4-dihydroxyphenylacetaldehyde, and 3,4-dihydroxyphenylglycoaldehyde (14). Recent studies have indicated that ALDH2 exerts protective effects on the cardio-cerebral vascular system and central nervous system. Single nucleotide polymorphisms (SNPs) of the ALDH2 gene have been reported to be associated with the risks for several diseases, such as coronary artery disease, ischemic stroke, digestive system cancer and allergic asthma. The A allele (ALDH2*2) of rs671, inherent in mainly the East Asian population, deregulates the ALDH2 activity intrinsically, and induces the accumulation of acetaldehyde. In 2000, Kamino et al. conducted the first case-control study in the Japanese population and found that the A allele and GA/AA genotypes are associated with an increased risk of AD (15). Subsequently, studies focusing on the association between ALDH2 polymorphisms and the risk of AD and PD have been continually published, but the results are inconsistent. Therefore, we conducted a meta-analysis of all available studies to investigate the precise association between the ALDH2 polymorphisms and the risk of AD and PD.

Materials and Methods

This meta-analysis of observational studies was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (16). All included data were collected from published studies, and no ethical issues were involved.

Search Strategy

Five online databases (PubMed, Embase, Web of Science, Chinese national knowledge infrastructure and Wanfang) were used to search for related studies on the association between ALDH2 polymorphisms and the risk of AD and PD from inception through May 10, 2018. Only the studies published in English and Chinese were included. The bibliographies of the collected studies and relevant reviews were also checked to identify potential additional articles. The following search terms and strategy was adopted (e.g., in PubMed):

  • #1 Aldehyde dehydrogenase 2

  • #2 Aldehyde Dehydrogenase-2

  • #3 ALDH2

  • #4 rs671

  • #5 rs4767944

  • #6 rs441

  • #7 #1 OR #2 OR #3 OR #4 OR #5 OR #6

  • #8 polymorphism

  • #9 variant

  • #10 mutation

  • #11 #8 OR #9 OR #10

  • #12 neurodegenerative disorders

  • #13 Alzheimer's disease

  • #14 Parkinson's disease

  • #15#12 OR #13 OR #14 OR #15

  • #16 #7 AND #11 AND #15.

Eligibility Criteria

The following were our inclusion criteria: (1) observation studies focusing on the association between ALDH2 polymorphisms and the risk of AD and PD; (2) studies containing sufficient data on the genotype in the control groups to evaluate crude odds ratios (ORs) and 95% confidence intervals (CIs); (3) studies published in English or Chinese, and (4) if overlapping or duplicate data were found on the same theme, only the largest or most recent sample data were included. The exclusion criteria included: (1) case report or review articles; (2) molecular biology research; (3) studies without efficient data; and (4) studies with duplicated or overlapping data.

Data Extraction and Quality Evaluation

Two authors (Chen and Huang) independently reviewed the included studies, and the following information was extracted and recorded for analysis: the first authors' name, publication date, study country, control design, genotyping method, sample sizes of the cases and controls, frequency data for the genotype distribution, assessment of Hardy-Weinberg equilibrium (HWE) in control, minor allele frequency, and disease type. The modified Newcastle-Ottawa scale (NOS) was used to evaluate the quality of all included studies (17). The scores ranged from 0 points (worst) to 11 points (best) (Supplementary Table 1). Studies with a score of 8 points or higher were classified as high quality.

Statistical Analysis

We calculated the crude ORs and 95% CIs to assess the statistical power of the association between ALDH2 polymorphisms and the risk of AD and PD. For example, the following five genetic models of the rs671 G>A locus were used: allele contrast (A vs. G), co-dominant models (GA vs. GG and AA vs. GG), dominant model (GA+AA vs. GG), and recessive model (AA vs. GG+GA). Heterogeneity among the included studies was examined using Cochran's Q tests and I2-tests (18). A fixed-effects model was adopted when I2 was ≤ 40%, but a random-effects model was adopted when I2 was > 40%(19, 20). Subgroup analyses were performed according to the HWE status, study country, disease type, control design (population-based and hospital-based), subject number, NOS evaluation and gender diversity. Meta-regression was conducted to identify which factors contributed to the existing heterogeneity. A cumulative meta-analysis was performed to assess the statistical tendency of the results. Sensitivity analysis was used to examine the stability of the results by sequentially removing each study individually. Potential publication biases were assessed with Egger's linear regression test and Begg's funnel plots (21, 22). All statistical analyses were performed using STATA version 14.0 (Stata Corporation, College Station, TX, USA). Statistical significance was set at < 0.05 (two-sided).

Results

Study Characteristics

We initially identified 154 relevant articles through our systematic literature search. The selection process is shown in Figure 1. According to the eligibility criteria, 45 studies were excluded following duplicate screening, 94 studies were removed after the subsequent title and abstract reviews, and 9 studies were eliminated because of deficient data, and/or similar/overlapping data. Finally, nine publications (11 independent studies) involving 2,283 patients and 3,032 controls were included (15, 23–30). Three common SNPs were reported; eight studies focused on the rs671 G>A polymorphism (15, 23–29), two studies focused on the rs4767944 C>T polymorphism (27, 30), and one study focused on the rs441 T>C polymorphism (27). In all included studies, most subjects were from East Asians countries including China, Japan, and Korea, except for one study that was performed in the Iranian population (30). The HWE assessment of control revealed that there were two studies that deviated from or lacked the HWE index in the rs671 G>A polymorphism (15, 23), and one study each that deviated from the HWE in the s4767944 C>T polymorphism (27) and rs441T>C polymorphism (27). The characteristics of all included studies are presented in Table 1.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of the study selection process.

Table 1.

Characteristics of case-control studies on ALDH2 polymorphisms and AD and PD risk.

References Country Control design Genotype method Case Control Genotype distribution P for HWE MAF NOS evaluation Disease type
Case Control
Rs671 GG GA AA GG GA AA
Kamino et al. (15) Japan HB PCR-RFLP 447 447 232 183 32 280 138 29 0.04 0.22 7 AD
Kim et al. (23) Korea PB PCR-RFLP 80 610 60a 20b 435a 175b NA NA 7 AD
Wang et al. (24) China HB PCR-RFLP 188 223 54 92 42 124 84 15 0.88 0.26 7 AD
Zhou et al., (25) China HB PCR-RFLP 106 100 65 32 9 54 38 8 0.72 0.27 7 AD
Komatsu et al. (26) Japan PB TaqMan 158 130 81 62 15 67 54 9 0.67 0.28 8 AD
Ma et al., (29) China HB PCR-RFLP 115 236 72 30 13 177 52 7 0.20 0.14 7 AD
Zhang et al. (27) China HB PCR-RFLP 584 582 321 236 27 339 208 35 0.68 0.24 9 PD
Zhao et al. (28) China HB PCR-RFLP 115 214 71 32 12 157 52 5 0.78 0.14 7 PD
Rs4767944 CC CT TT CC CT TT
Zhang et al. (27) China HB PCR-RFLP 584 582 92 316 176 62 301 219 0.01 0.63 8 PD
Madadi et al. (30) Iran HB PCR-RFLP 490 490 339 143 9 344 133 13 0.97 0.16 8 PD
Rs441 TT TC CC TT TC TT
Zhang et al. (27) China HB PCR-RFLP 584 582 281 278 25 293 256 33 0.02 0.28 8 PD
Open in a new tab

HWE in control.

NA, Not available.

a

Data of the GG genotype;

b

Data of the GA/AA genotypes.

HB, Hospital or healthy based; PB, Population based.

AD, Alzheimer's disease; PD, Parkinson's disease.

Quantitative and Subgroup Analyses

Association between the rs671 polymorphism and the risk of AD and PD. There were six case-control studies involving 2,840 subjects focused on the association between the rs671 polymorphism and AD risk. The aggregated results indicated an increased risk of the rs671 G>A polymorphism in patients with AD (A vs. G: OR = 1.46, 95%CI = 1.01–2.11, P = 0.05, I2 = 84.2% (Figure 2); AA vs. GG: OR = 2.22, 95%CI = 1.03–4.77, P = 0.04, I2 = 79.2%; AA vs. GG+GA: OR = 1.94, 95%CI = 1.03–3.64, P = 0.04, I2 = 71.1%). Subgroup analyses also revealed an increased AD risks in Chinese (AA vs. GG: OR = 3.15, 95%CI = 1.03–9.65, P = 0.04, I2 = 79.6%; AA vs. GG+GA: OR = 2.75, 95%CI = 1.23–6.14, P = 0.02, I2 = 63.0%) and Japanese (A vs. G: OR = 1.54, 95%CI = 1.00–2.36, P = 0.05, I2 = 17.1%) on the basis of country difference. The subsequent analysis based on the HWE status and other subgroup revealed the similar increased associations (Table 2, Supplementary Figure S1 for other models) Heterogeneity was observed in all five genetic models; the meta-regression analysis was conducted with the above-mentioned stratified factors and did not identify any factor that contributed to the existing heterogeneity (e.g., A vs. G model: P = 0.89 for HWE status, P = 0.53 for study country, P = 0.53 for control design, P = 0.89 for subject number, and P = 0.53 for NOS evaluation).

Figure 2.

Figure 2

Open in a new tab

OR and 95% CIs of the associations between ALDH2 rs671 G>A polymorphism and AD risk in A vs. G model.

Table 2.

Summary ORs and 95% CI of ALDH2 polymorphisms and AD and PD risk.

N* OR 95% CI P I2(%) OR 95% CI P I2(%) OR 95% CI P I2(%) OR 95% CI P I2(%) OR 95% CI P I2(%)
rs671 A vs. G GA vs. GG AA vs. GG GA+AA vs. GG AA vs. GG+GA
AD Total 6 1.46 1.01–2.11 0.05 84.2 1.35 0.91–1.99 0.13 73.9 2.22 1.03–4.77 0.04 79.2 1.36 0.90–2.03 0.14 81.0 1.94 1.03–3.64 0.04 71.1
HWE–yes 4 1.48 0.88–2.49 0.14 87.4 1.26 0.72–2.21 0.41 79.4 2.57 1.01–6.53 0.05 78.1 1.45 0.77–2.73 0.25 86.0 2.23 1.18–4.60 0.01 61.4
HWE–no 2 1.36 1.10–1.69 0.01 NA 1.60 1.21–2.12 0.001 NA 1.33 0.78–2.27 0.29 NA 1.19 0.64–2.18 0.58 76.4 1.11 0.66–1.87 0.69 NA
COUNTRY
China 3 1.64 0.87–3.10 0.12 88.3 1.39 0.67–2.85 0.38 83.0 3.15 1.03–9.65 0.04 79.6 1.63 0.74–3.62 0.23 87.9 2.75 1.23–6.14 0.02 63.0
Japan 2 1.54 1.00–2.36 0.05 17.1 1.28 0.77–2.13 0.33 69.7 1.34 0.85–2.12 0.20 0 1.31 0.87–1.98 0.20 59.6 1.18 0.76–1.85 0.46 0
CONTROL DESIGN
HB 4 1.57 1.02–2.42 0.04 86.0 1.47 0.95–2.27 0.09 74.6 2.48 0.98–6.30 0.06 83.4 1.63 0.99–2.67 0.05 82.7 2.10 0.96–357 0.06 77.6
PB 2 1.07 0.75–1.54 0.71 NA 0.95 0.58–1.55 0.84 NA 1.38 0.57–3.35 0.48 NA 0.93 0.65–1.32 0.68 0 1.41 0.60–3.34 0.43 NA
SUBJECTS
>500 2 1.36 1.10–1.69 0.01 NA 1.60 1.21–2.12 0.001 NA 1.33 0.78–2.27 0.29 NA 1.19 0.64–2.18 0.58 76.4 1.11 0.66–1.87 0.69 NA
< 500 4 1.48 0.88–2.49 0.14 87.4 1.26 0.72–2.21 0.41 79.4 2.57 1.01–6.53 0.05 78.1 1.45 0.77–2.73 0.25 86.0 2.23 1.18–4.60 0.01 61.4
NOS EVALUATION
NOS < 8 5 1.57 1.02–2.42 0.04 86.0 1.47 0.95–2.27 0.09 74.6 2.48 0.98–6.30 0.06 83.4 1.43 0.90–2.28 .92–2.18 0.13 82.9 2.10 0.96–357 0.06 77.6
NOS ≥8 1 1.07 0.75–1.54 0.71 NA 0.95 0.58–1.55 0.84 NA 1.38 0.57–3.35 0.748 NA 1.01 0.64–1.61 0.96 NA 1.41 0.60–3.34 0.43 NA
GENDER
Male 2 1.52 1.06–2.16 0.02 0 1.70 1.07–2.70 0.03 14.3 1.81 0.73–4.46 0.20 0 1.72 1.10–2.67 0.02 0 1.47 0.60–3.58 0.40 0
Female 2 0.90 0.40–2.10 0.79 83.4 0.94 0.35–2.57 0.891 81.5 0.93 0.37–2.32 0.88 43.8 0.91 0.33–1.2.49 0.86 84.3 0.98 0.57–1.69 0.95 0
PD Total 2 1.38 0.77–2.45 0.28 85.2 1.23 0.98–1.52 0.07 0 1.95 0.31–12.23 0.47 89.3 1.30 0.90–1.92 0.15 53.6 1.18 0.29–11.16 0.52 89.4
Rs4767944 T vs. C CT vs. CC TT vs. CC CT+TT vs. CC TT vs. CC+CT
PD Total 2 0.87 0.67–1.14 0.31 70.9 0.89 0.58–1.36 0.60 71.3 0.57 0.40–0.80 < 0.01 0 0.83 0.51–1.36 0.46 80.3 0.71 0.56–0.90 0.01 0
Open in a new tab

The accumulative analysis presented fluctuating findings and the results tending to show a potential association by Ma et al. (29) (Figure 3 for A vs. G model, Supplementary Figure S2 for other models). A sensitivity analysis was conducted by removing each included study, and fluctuating results were observed after several studies were removed (Figure 4 for A vs. G model, Supplementary Figure S3 for other models).

Figure 3.

Figure 3

Open in a new tab

Cumulative meta-analyses according to publication year in A vs. G model of ALDH2 rs671 G>A polymorphism and AD risk.

Figure 4.

Figure 4

Open in a new tab

Sensitivity analysis through deleting each study to reflect the influence of the individual dataset to the pooled ORs in A vs. G model of ALDH2 rs671 G>A polymorphism and AD risk.

Publication biases were investigated, and the results did not show any obvious asymmetry in the five funnel plots (Figure 5 for A vs. G model, Supplementary Figure S4 for other models). All results were confirmed with Egger's linear regression test (A vs. G, P = 0.76; GA vs. GG: P = 0.40; AA vs. GG, P = 0.94; GA+AA vs. GG, P = 0. 42; AA vs. GG+GA, P = 0.77).

Figure 5.

Figure 5

Open in a new tab

Funnel plot analysis to detect publication bias for A vs. G model of ALDH2 rs671 G>A polymorphism and AD risk. Circles represent the weight of the studies.

Two case-control studies involving 1,495 subjects focused on the association between the rs671 polymorphism and PD risk and presented a negative relationship (Table 2).

Association between the rs4767944 and rs441 polymorphisms and the risk of PD. Two studies with 2,146 subjects focused on the association between the rs4767944 polymorphism and the risk of PD. The results of our aggregated analysis showed that the rs4767944 C>T polymorphism increased the PD risk in the homozygous model, but not in other genetic models. Only one study focused on the association between the rs441 polymorphisms and the risk of PD. The related information about the rs441 polymorphism is presented in Table 1 (Quantitative calculation was not conducted).

Discussion

AD and PD are the most important neurodegenerative disorders. The most intensively studied neurodegenerative disease is AD, which is known to be an established cause of aging-associated dementia, accounting for 60–70% of all neurodegenerative cases (31). Autopsy reports have demonstrated that the brain tissues of individuals with AD exhibit atrophied neurons, intraneuronal neurofibrillary tangles, and amyloid plaques. The amyloid beta accumulation promotes oxidative stress and leads to mitochondrial dysfunction. As for PD, it is a chronic neurodegenerative disease without a clear etiology and is characterized by the classic triad of tremors, bradykinesia, and rigidity (32). Research has shown that >50% of patients with PD will develop dementia within 10 years after the initial diagnosis (33). The prominent pathological changes that occur in patients with PD are the degeneration of dopamine neurons in the mesencephalon, which causes a decrease of the dopamine content in the striatum.

Alcohol consumption is one of the most common habits of human beings. Alcohol is characterized by a high affinity for water and can be quickly distributed throughout the body after rapid absorption into the blood from the gastrointestinal tract. The majority of ethanol metabolism occurs in the liver and ALDH2 has a strong effect on acetaldehyde metabolism and accumulation (34). Current evidence suggests that alcohol intake can have two opposing effects on health. Specifically, consuming small doses of alcohol is believed to confer protection and decrease the risk of cardiovascular system dysfunction (35), while consuming large doses of ethanol can increase the alcohol content in the serum and seriously threaten human health, leading to cardiovascular disease and various oncological diseases. Most studies suggest that long-term and excessive alcohol consumption may damage the central nervous system cells and impair cognitive function (36).

Several important SNP loci have been identified and studied in the ALDH2 gene. These SNPs change the nucleotide bases of the human genome, thus altering the protein expression levels and biological activity. The rs671 polymorphism is caused by a single-nucleotide mutation from G to A, which encodes an amino acid change from glutamate to lysine. Rs671is the most well-known dysfunctional SNP, and both the GA and AA genotypes severely reduce the activity of the ALDH2 enzyme and impair ethanol metabolism (37). The mutant genotypes and allele frequencies of rs671 are markedly different among different populations and are particularly more prevalent in East Asian populations (Chinese, Japanese and Korean individuals) than in other populations (38, 39). Many studies have demonstrated that the ALDH2 rs671 G>A polymorphism maybe associated with the development of various diseases, such as digestive system cancer (40), diabetes (41), coronary heart disease (42), and ischemic stroke (43), especially in East Asians.

Since 2000, an increasing number of studies have focused on the relationship between ALDH2 polymorphisms and the risk of AD. Kamino et al. conducted the first case-control study and found that the rs671 A allele would increase the risk for AD in the Japanese population (OR = 1.6, 95% CI = 1.19–2.03), and this trend was observed in both males and females. Wang et al. found an apparently increased AD risk in Chinese individuals with the rs671 A-allele (OR = 3.11, 95%CI = 2.06–4.69). Similarly, Zhao et al. and Ma et al. reported the similar elevated risk for PD (28) and AD with the rs671G>A mutation (29). However, Zhou et al., Komatsu et al., and Zhang et al. did not find any potential relationship between the rs671 G>A polymorphism and the risk of AD. Therefore, the discrepancies in these result promoted us to conduct this meta-analysis to investigate the precise association based on published studies.

To our knowledge, this is the first meta-analysis on the association between the ALDH2 rs671 G>A polymorphism and the risk of AD and PD. All results suggest that the polymorphism locus of ALDH2 rs671 G>A may be a potential risk factor for AD but not for PD in the East Asians. The current evidence indicated that the carriers with AA genotype were more dangerous compared with the GG genotype, which was also coincides with the decrease of ALDH2 protein activity that caused by allele A mutation. Moreover, the elevated risks we identified were also observed in some subgroups, such as in male groups. Among East Asians, males account for the majority of people who consume alcohol. The interactive effects of alcohol consumption and the deficient ALDH2 enzymatic activity caused by the rs671 mutation may contribute to AD development in males. Two of the studies we evaluated focused on the rs4767944 polymorphism, and the results revealed a slightly protective effect of this polymorphism against PD. In addition, no positive association was identified between rs441 polymorphism and the risk of PD with only one study. However, given the limited number of studies and included participants for this polymorphism, the results might not reflect the real relationship. Therefore, additional studies examining the association between the rs4767944 and rs441 polymorphisms and the risk of PD are necessary.

Given the inherent deficiencies in meta-analyses, this study has some limitations that should be considered when interpreting our findings. First, all subjects in the included studies were from East Asian countries. As such, the pooled results of this meta-analysis only reflect the East Asian population and thus are not generalizable to other ethnicities. Second, a slightly large sample size was only available for the ALDH2 rs671 G>A polymorphism, but not for the rs4767944 and rs441 polymorphisms. The investigations of the associations of each of the three polymorphisms with the risk of AD and PD were conducted independently without adjusting for gene-gene interactions, such as through a haplotype analysis. Third, the interactions with some factors, such as body mass index, blood pressure, and unhealthy living habits, were not examined because of the lack of accurate individual information in the included studies. Finally, heterogeneity was observed in some of the genetic models in all included studies, and the meta-regression failed to identify any factors that contributed to the heterogeneity. Future studies that address these limitations will be required before any concrete conclusions about the relationships between these polymorphisms and AD and PD can be made.

In conclusion, the present results indicate that the ALDH2 rs671 G>A polymorphism may be a potential risk factor for AD. Additional case-control studies are needed to investigate the underlying mechanism of the potential risk.

Author Contributions

JC, WH, and LZ conceived the study and wrote the draft of the paper. JC, WH, and Y-YH searched the databases and extracted the data. C-HC and G-BJ analyzed the data and reviewed the manuscript. All the authors approved the final manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. This study was supported by the Foundations of the Science and Technology Department of Hubei Province (No. 2016CFB567, 2014CFB364), and the Hubei Province health and family planning scientific research project (No. WJ2017F069, WJ2015Q041) and Taihe Hospital (2016BSQD02). The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.00290/full#supplementary-material

Click here for additional data file. (15.7KB, docx)
Click here for additional data file. (15.2KB, docx)
Click here for additional data file. (450.1KB, tiff)
Click here for additional data file. (226.2KB, tiff)
Click here for additional data file. (517.8KB, tiff)
Click here for additional data file. (220.3KB, TIFF)

References

  • 1.Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. (2009) 62:42–52. 10.1016/j.neuron.2009.03.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Matilla-Duenas A, Corral-Juan M, Rodriguez-Palmero Seuma A, Vilas D, Ispierto L, Morais S, et al. Rare neurodegenerative diseases: clinical and genetic update. Adv Exp Med Biol. (2017) 1031:443–96. 10.1007/978-3-319-67144-4_25 [DOI] [PubMed] [Google Scholar]
  • 3.Ridolfi B, Abdel-Haq H. Neurodegenerative disorders treatment: the MicroRNA role. Curr Gene Ther. (2017) 17:327–63. 10.2174/1566523218666180119120726 [DOI] [PubMed] [Google Scholar]
  • 4.Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. (2013) 80:1778–83. 10.1212/WNL.0b013e31828726f5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gammon K. Neurodegenerative disease: brain windfall. Nature. (2014) 515:299–300. 10.1038/nj7526-299a [DOI] [PubMed] [Google Scholar]
  • 6.Maiti P, Dunbar GL. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci. (2018) 19:E1637. 10.3390/ijms19061637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, et al. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheim Dement. (2015) 11:394–403 e391. 10.1016/j.jalz.2013.12.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yang Y, Song W. Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience. (2013) 250:140–50. 10.1016/j.neuroscience.2013.07.009 [DOI] [PubMed] [Google Scholar]
  • 9.Gelders G, Baekelandt V, Van der Perren A. Linking neuroinflammation and neurodegeneration in Parkinson's disease. J Immunol Res. (2018) 2018:4784268. 10.1155/2018/4784268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen H, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, et al. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet. (2017) 389:718–26. 10.1016/S0140-6736(16)32399-6 [DOI] [PubMed] [Google Scholar]
  • 11.Xu W, Tan L, Wang HF, Jiang T, Tan MS, Zhao QF, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry. (2015) 86:1299–306. 10.1136/jnnp-2015-310548 [DOI] [PubMed] [Google Scholar]
  • 12.Li Z, Del-Aguila JL, Dube U, Budde J, Martinez R, Black K, et al. Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med. (2018) 10:43. 10.1186/s13073-018-0551-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Freudenberg-Hua Y, Li W, Davies P. The role of genetics in advancing precision medicine for alzheimer's disease-a narrative review. Front Med. (2018) 5:108. 10.3389/fmed.2018.00108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chen CH, Joshi AU, Mochly-Rosen D. The role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in neuropathology and neurodegeneration. Acta Neurol Taiwan. (2016) 25:111–23. [PMC free article] [PubMed] [Google Scholar]
  • 15.Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, et al. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophys Res Commun. (2000) 273:192–6. 10.1006/bbrc.2000.2923 [DOI] [PubMed] [Google Scholar]
  • 16.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. (2009) 339:b2535. 10.1136/bmj.b2535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Niu YM, Weng H, Zhang C, Yuan RX, Yan JZ, Meng XY, et al. Systematic review by multivariate meta-analyses on the possible role of tumor necrosis factor-alpha gene polymorphisms in association with ischemic stroke. Neuromolecular Med. (2015) 17:373–84. 10.1007/s12017-015-8365-7 [DOI] [PubMed] [Google Scholar]
  • 18.Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. (2006) 11:193–206. 10.1037/1082-989X.11.2.193 [DOI] [PubMed] [Google Scholar]
  • 19.Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. (1959) 22:719–48. [PubMed] [Google Scholar]
  • 20.DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. (1996) 15:1237–1248; discussion 1249–1252. [DOI] [PubMed] [Google Scholar]
  • 21.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088–101. 10.2307/2533446 [DOI] [PubMed] [Google Scholar]
  • 22.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. 10.1136/bmj.315.7109.629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kim JM, Stewart R, Shin IS, Jung JS, Yoon JS. Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer's disease in an older Korean population. Neurobiol Aging. (2004) 25:295–301. 10.1016/S0197-4580(03)00114-3 [DOI] [PubMed] [Google Scholar]
  • 24.Wang B, Wang J, Zhou S, Tan S, He X, Yang Z, et al. The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neurol Sci. (2008) 268:172–5. 10.1016/j.jns.2007.12.006 [DOI] [PubMed] [Google Scholar]
  • 25.Zhou S, Huriletemuer, Wang J, Zhang C, Zhao S, Wang de S, et al. Absence of association on aldehyde dehydrogenase 2 (ALDH2) polymorphism with Mongolian Alzheimer patients. Neurosci Lett. (2010) 468:312–5. 10.1016/j.neulet.2009.11.022 [DOI] [PubMed] [Google Scholar]
  • 26.Komatsu M, Shibata N, Ohnuma T, Kuerban B, Tomson K, Toda A, et al. Polymorphisms in the aldehyde dehydrogenase 2 and dopamine beta hydroxylase genes are not associated with Alzheimer's disease. J Neural Transm. (2014) 121:427–32. 10.1007/s00702-013-1112-z [DOI] [PubMed] [Google Scholar]
  • 27.Zhang X, Ye YL, Wang YN, Liu FF, Liu XX, Hu BL, et al. Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson's disease in Han Chinese population. Neurobiol Aging. (2015) 36:2660 e2669–13. 10.1016/j.neurobiolaging.2015.06.001 [DOI] [PubMed] [Google Scholar]
  • 28.Zhao CC, Cai HB, Wang H, Pan SY. Role of ADH2 and ALDH2 gene polymorphisms in the development of Parkinson's disease in a Chinese population. Genet Mol Res. (2016) 15. 10.4238/gmr.15038606 [DOI] [PubMed] [Google Scholar]
  • 29.Ma L, Lu ZN. Role of ADH1B rs1229984 and ALDH2 rs671 gene polymorphisms in the development of Alzheimer's disease. Genet Mol Res. (2016) 15. 10.4238/gmr.15048740 [DOI] [PubMed] [Google Scholar]
  • 30.Madadi F, Khaniani MS, Shandiz EE, Ayromlou H, Najmi S, Emamalizadeh B, et al. Genetic analysis of the ZNF512B, SLC41A1, and ALDH2 polymorphisms in Parkinson's disease in the iranian population. Genet Test Mol Biomarkers. (2016) 20:629–32. 10.1089/gtmb.2016.0133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. (2006) 368:387–403. 10.1016/S0140-6736(06)69113-7 [DOI] [PubMed] [Google Scholar]
  • 32.Assadeck H, Daouda MT, Djibo FH, Maiga DD, Omar EA. Clinical profile of Parkinson's disease: experience of niger. J Neurosci Rural Pract. (2018) 9:214–8. 10.4103/jnrp.jnrp_337_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Korczyn AD. Mild cognitive impairment in Parkinson's disease. J Neural Transm. (2013) 120:517–21. 10.1007/s00702-013-1006-0 [DOI] [PubMed] [Google Scholar]
  • 34.Heit C, Dong H, Chen Y, Thompson DC, Deitrich RA, Vasiliou VK. The role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system. Subcell Biochem. (2013) 67:235–47. 10.1007/978-94-007-5881-0_8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.de Gaetano G, Costanzo S, Di Castelnuovo A, Badimon L, Bejko D, Alkerwi A, et al. Effects of moderate beer consumption on health and disease: a consensus document. Nutr Metab Cardiovasc Dis. (2016) 26:443–67. 10.1016/j.numecd.2016.03.007 [DOI] [PubMed] [Google Scholar]
  • 36.Hassing LB. Light alcohol consumption does not protect cognitive function: a longitudinal prospective study. Front Aging Neurosci. (2018) 10:81 10.3389/fnagi.2018.00081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Peng GS, Yin SJ. Effect of the allelic variants of aldehyde dehydrogenase ALDH2*2 and alcohol dehydrogenase ADH1B*2 on blood acetaldehyde concentrations. Hum Genomics. (2009) 3:121–7. 10.1186/1479-7364-3-2-121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sakiyama M, Matsuo H, Nakaoka H, Yamamoto K, Nakayama A, Nakamura T, et al. Identification of rs671, a common variant of ALDH2, as a gout susceptibility locus. Sci Rep. (2016) 6:25360. 10.1038/srep25360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, et al. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet. (1992) 88:344–6. 10.1007/BF00197271 [DOI] [PubMed] [Google Scholar]
  • 40.Hidaka A, Sasazuki S, Matsuo K, Ito H, Sawada N, Shimazu T, et al. Genetic polymorphisms of ADH1B, ADH1C and ALDH2, alcohol consumption, and the risk of gastric cancer: the Japan Public Health Center-based prospective study. Carcinogenesis. (2015) 36:223–31. 10.1093/carcin/bgu244 [DOI] [PubMed] [Google Scholar]
  • 41.Li GY, Li ZB, Li F, Dong LP, Tang L, Xiang J, et al. Meta-analysis on the association of ALDH2 polymorphisms and type 2 diabetic mellitus, diabetic retinopathy. Int J Environ Res Public Health. (2017) 14:165. 10.3390/ijerph14020165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Li YY, Wang H, Wu JJ, Kim HJ, Yang XX, Geng HY, et al. ALDH2 gene G487A polymorphism and coronary artery disease: a meta-analysis including 5644 participants. J Cell Mol Med. (2018) 22:1666–74. 10.1111/jcmm.13443 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sung YF, Lu CC, Lee JT, Hung YJ, Hu CJ, Jeng JS, et al. Homozygous ALDH2*2 is an independent risk factor for ischemic stroke in taiwanese men. Stroke. (2016) 47:2174–9. 10.1161/STROKEAHA.116.013204 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (15.7KB, docx)
Click here for additional data file. (15.2KB, docx)
Click here for additional data file. (450.1KB, tiff)
Click here for additional data file. (226.2KB, tiff)
Click here for additional data file. (517.8KB, tiff)
Click here for additional data file. (220.3KB, TIFF)

Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA

RESOURCES